JP2023538236A5 - - Google Patents

Info

Publication number
JP2023538236A5
JP2023538236A5 JP2023504727A JP2023504727A JP2023538236A5 JP 2023538236 A5 JP2023538236 A5 JP 2023538236A5 JP 2023504727 A JP2023504727 A JP 2023504727A JP 2023504727 A JP2023504727 A JP 2023504727A JP 2023538236 A5 JP2023538236 A5 JP 2023538236A5
Authority
JP
Japan
Prior art keywords
composition according
composition
liver disease
peptide
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2021/010910 external-priority patent/WO2022035302A1/ko
Publication of JP2023538236A publication Critical patent/JP2023538236A/ja
Publication of JP2023538236A5 publication Critical patent/JP2023538236A5/ja
Pending legal-status Critical Current

Links

JP2023504727A 2020-08-14 2021-08-17 グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物 Pending JP2023538236A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2020-0102604 2020-08-14
KR20200102604 2020-08-14
KR10-2021-0048006 2021-04-13
KR20210048006 2021-04-13
PCT/KR2021/010910 WO2022035302A1 (ko) 2020-08-14 2021-08-17 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물

Publications (2)

Publication Number Publication Date
JP2023538236A JP2023538236A (ja) 2023-09-07
JP2023538236A5 true JP2023538236A5 (cg-RX-API-DMAC7.html) 2024-08-27

Family

ID=80247176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504727A Pending JP2023538236A (ja) 2020-08-14 2021-08-17 グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物

Country Status (10)

Country Link
US (1) US20240024426A1 (cg-RX-API-DMAC7.html)
EP (1) EP4197550A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023538236A (cg-RX-API-DMAC7.html)
KR (1) KR20220021895A (cg-RX-API-DMAC7.html)
CN (1) CN116322786A (cg-RX-API-DMAC7.html)
AU (1) AU2021326369A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188884A1 (cg-RX-API-DMAC7.html)
IL (1) IL300017A (cg-RX-API-DMAC7.html)
MX (1) MX2023001601A (cg-RX-API-DMAC7.html)
WO (1) WO2022035302A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537895A (ja) * 2020-08-14 2023-09-06 ハンミ ファーマシューティカル カンパニー リミテッド 三重活性体持続型結合体を有効成分として含む薬学組成物
WO2022065897A1 (ko) * 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도
EP4230218A4 (en) * 2020-10-16 2024-11-20 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating vasculitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU2014345570B2 (en) * 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
JP6280398B2 (ja) * 2014-03-04 2018-02-14 株式会社ナガセビューティケァ Glp−1分泌促進剤
TWI772252B (zh) * 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
FI3322437T3 (fi) * 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
US20180360973A1 (en) * 2015-12-02 2018-12-20 Hanmi Pharm. Co., Ltd. Protein conjugate using a fatty acid derivative and method for preparation thereof
JP6712323B2 (ja) * 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体
AR110300A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
JP2023537895A (ja) * 2020-08-14 2023-09-06 ハンミ ファーマシューティカル カンパニー リミテッド 三重活性体持続型結合体を有効成分として含む薬学組成物

Similar Documents

Publication Publication Date Title
JP2022551282A5 (cg-RX-API-DMAC7.html)
JP2017533194A5 (cg-RX-API-DMAC7.html)
RU2017112738A (ru) Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
JP2023504914A5 (cg-RX-API-DMAC7.html)
JP2022518210A5 (cg-RX-API-DMAC7.html)
JP2014530868A5 (cg-RX-API-DMAC7.html)
CN117794946A (zh) 长效双重gip/glp-1肽缀合物及使用方法
JP2022504153A5 (cg-RX-API-DMAC7.html)
JP2020512287A5 (cg-RX-API-DMAC7.html)
JP2023502005A5 (cg-RX-API-DMAC7.html)
IL300017A (en) A hypotensive pharmaceutical composition that includes a triple activator with activity against all glucagon, GLP-1 and GIP receptors
CN102666580A (zh) 抗原性glp-1类似物的糖链加成物
JP2012531219A5 (cg-RX-API-DMAC7.html)
FI3936142T3 (fi) Kaikkien glukagoni-, glp-1- ja gip-reseptorien suhteen aktiivisuutta omaava kolmoisagonisti maksasairauden hoitoon
JP2026004299A5 (cg-RX-API-DMAC7.html)
JP2023549854A5 (cg-RX-API-DMAC7.html)
JP2024500605A5 (cg-RX-API-DMAC7.html)
CN114829377A (zh) 用于预防和/或治疗hbv和/或hdv感染、肝脏疾病和用于靶向ntcp的偶联化合物
JP2023511184A5 (cg-RX-API-DMAC7.html)
CN114685646A (zh) 一种多肽侧链类似物的制备方法及其应用
IL299778A (en) Therapeutic use of glucagon derivative or conjugate thereof for liver disease
JP2022516660A5 (cg-RX-API-DMAC7.html)
JP6368706B2 (ja) シアリル化糖鎖が付加されたポリペプチド
JP2024527220A5 (cg-RX-API-DMAC7.html)
WO2020066343A1 (ja) 細胞膜透過性ペプチド